[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

151 Donor-Derived Anti-CD19 Chimeric-Antigen-Receptor-Expressing T Cells Cause Regression Of Malignancy Persisting After Allogeneic Hematopoietic Stem Cell TransplantationClinically Relevant Abstract

Program: Oral and Poster Abstracts
Type: Oral
Session: 723. Clinical Allogeneic and Autologous Transplantation - Late Complications and Approaches to Disease Recurrence: Relapse after Transplantation - Novel Strategies
Sunday, December 8, 2013: 5:00 PM
Riverside Rooms - R06-R07 (Ernest N. Morial Convention Center)

James N Kochenderfer, M.D.1, Mark E. Dudley, Ph.D.2*, Robert O. Carpenter1*, Sadik H Kassim, Ph.D.3*, Jeremy J. Rose4*, William Telford, Ph.D.5*, Frances T Hakim, PhD6*, David Halverson, MD7*, Daniel H. Fowler, MD1*, Nancy M. Hardy, MD8, Anthony Mato9, Dennis D. Hickstein, M.D.10, Juan Gea-Banacloche, MD11*, Steven Z. Pavletic, MD12, Claude Sportes, MD13*, Irina Maric, MD14, Steven Feldman, Ph.D.2*, Brenna G Hansen, RN5*, Jennifer Wilder, RN15*, Bazetta Blacklock-Schuver, RN1*, Bipulendu Jena, PhD16*, Michael Bishop, MD17*, Steven A. Rosenberg, M.D., Ph.D.2* and Ronald E. Gress, MD18

1Experimental Transplantation and Immunology Branch, National Cancer Institute, Bethesda, MD
2Surgery Branch, NCI, Bethesda, MD
3Surgery Branch, NCI, Bethesda
4ETIB, NCI, Bethesda, MD
5Experimental Transplantation and Immunology Branch, NCI, Bethesda
6Experimental Transplantation and Immunology Branch, National Cancer Institute, Center for Cancer Research, Bethesda, MD
7Experimental Transplantation and Immunology Branch, NCI, Bethesda, MD
8Experimental Transplantation and Immunology Branch, NIH/National Cancer Institute, Bethesda, MD
9John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ
10Experimental Transplantation and Immunology Branch, National Cancer Institute, NIH, Bethesda, MD
11National Cancer Institute, National Institutes of Health, Bethesda, MD
12Experimental Transplant and Immunology Branch, National Institutes of Health, National Cancer Institute, Bethesda, MD
13Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
14Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD
15Clinical Research Directorate/CMRP, SAIC, Frederick, MD
16Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX
17Department of Medicine, Section Hematology/Oncology, University of Chicago Medical Center, Chicago, IL
18Experimental Transplantation and Immunology Branch, National Institutes of Health, National Cancer Institute, Bethesda, MD

Progressive malignancy is a leading cause of death in patients undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT).  To improve treatment of B-cell malignancies that persist despite alloHSCT, we conducted a clinical trial of allogeneic T cells genetically modified to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19.  Ten patients were treated on this trial.  Four patients were recipients of human-leukocyte-antigen (HLA)-matched unrelated donor (URD) transplants and 6 patients were recipients of HLA-matched sibling transplants.  T cells for genetic modification were obtained from each patient’s healthy alloHSCT donor.  Patients received a single infusion of anti-CD19-CAR T cells.  Cell doses ranged from 1x106 to 10x106 T cells/kg.  A mean of 58% of the infused cells expressed the CAR.  Patients did not receive chemotherapy or other anti-malignancy therapy with the CAR-T-cell infusions, so the responses observed in these patients are not confounded by the effects of chemotherapy.  In contrast to other reports of successful treatment of B-cell malignancies with anti-CD19-CAR T cells, the patients on this study were not lymphocyte-depleted at the time of the CAR-T-cell infusions. 

                Two patients with chronic lymphocytic leukemia (CLL) refractory to standard unmanipulated allogeneic donor lymphocyte infusions (DLIs) had regressions of large malignant lymph node masses after infusion of allogeneic anti-CD19-CAR T cells.  One of these CLL patients obtained a complete remission that is ongoing 9 months after treatment with allogeneic anti-CD19-CAR T cells.  This patient also had complete eradication of blood B cells within 9 days after her CAR-T-cell infusion.  Another patient had tumor lysis syndrome requiring rasburicase treatment as his CLL dramatically regressed in lymph nodes, bone marrow, and blood within 2 weeks of his anti-CD19-CAR-T-cell infusion.  A patient with mantle cell lymphoma obtained a partial remission that is ongoing 3 months after infusion of anti-CD19-CAR T cells.  A fourth patient with diffuse large B-cell lymphoma has ongoing stable disease 11 months after infusion of anti-CD19-CAR T cells.  The other 6 treated patients all had short periods of stable malignancy or progressive disease after their CAR-T-cell infusions.  Specific eradication of blood B cells occurred after infusion of CAR T cells in 3 of 4 patients with measurable blood B cells pretreatment.  None of the patients treated on this study developed GVHD after their anti-CD19-CAR-T-cell infusions, despite the fact that 6 of 10 treated patients had experienced GVHD at earlier time-points after their most recent alloHSCT.  One patient, who had a history of cardiac dysfunction with prior acute illnesses, had temporary cardiac dysfunction after infusion of anti-CD19-CAR T cells. The most prominent toxicities experienced by patients were fever and hypotension; these peaked 5 to 12 days after CAR-T-cell infusions and resolved within 14 days after the T-cell infusions.  Two patients had Grade 3 fever, and 2 patients had Grade 3 hypotension.  No patients experienced Grade 4 toxicities that were attributable to the CAR-T-cell infusions.  Elevated levels of serum interferon gamma were detected in 3 patients at the time that they were experiencing toxicities. 

                We detected cells containing the anti-CD19-CAR gene in the blood of 8 of 10 patients.  The peak blood levels of CAR T cells varied from undetectable to 2.8% of peripheral blood mononuclear cells.  The persistence of the CAR T cells in the blood of patients was limited to one month or less.  When we assessed T cells from the blood of patients ex vivo, we found elevated levels of the T-cell inhibitory molecule programmed cell death protein-1 (PD-1) on CAR+ T cells compared to CAR-negative T cells.  These results show for the first time that small numbers of donor-derived allogeneic anti-CD19-CAR T cells can cause regression of highly treatment-resistant B-cell malignancies after alloHSCT without causing GVHD.  Malignancies that were resistant to standard DLIs regressed after anti-CD19-CAR-T-cell infusions.  Future goals for improving this approach include enhancing the persistence of anti-CD19-CAR T cells and reducing toxicities.  Infusion of allogeneic T cells genetically modified to recognize malignancy-associated antigens is a promising approach for treating residual malignancy after alloHSCT.

Disclosures: No relevant conflicts of interest to declare.

Previous Abstract | Next Abstract >>

*signifies non-member of ASH